TOLREMO therapeutics

Curated by Signal

Developing anti-cancer small molecules targeting novel drug resistance pathways

Overview

TOLREMO therapeutics is a developer of small molecules that target novel drug resistance pathways involved in cancer. The company has developed a screening platform for developing novel anti-drug resistance cancer drugs, and is also exploring the possibility of combining existing drugs to prevent drug resistance in cancer.

Key facts

Founded: 2017
Headquarters: Zurich, Switzerland
Stage: Sign up to view
Industry: Life Sciences Technology

Business model

1 product or service: Sign up to view

Contact

Email: Sign up to view

More on Vanberra Signal

Members only

Business overviewCore metrics and financials PeopleLeadership and key people Similar companiesPeers and competitors Deep AnalysisAI-generated strategic report

Competitors & similar companies

More Life Sciences Technology companies

Helixstreet
Ethereum-based DNA analytics solution
Life Sciences TechnologyBasel, Switzerland
Pneumoscope
Developer of AI-based stethoscope
Life Sciences TechnologySwitzerland
Daysy
Smart fertility tracking thermometer
Life Sciences TechnologyZurich, Switzerland

About TOLREMO therapeutics

What does TOLREMO therapeutics do?

TOLREMO therapeutics is a developer of small molecules that target novel drug resistance pathways involved in cancer.

Where is TOLREMO therapeutics headquartered?

TOLREMO therapeutics is headquartered in Zurich, Switzerland.

When was TOLREMO therapeutics founded?

TOLREMO therapeutics was founded in 2017.

Which sector is TOLREMO therapeutics in?

TOLREMO therapeutics operates in Life Sciences Technology.

Who are TOLREMO therapeutics's competitors?

Companies similar to TOLREMO therapeutics include Helixstreet, Pneumoscope, and Daysy.